Investors looking for income from ETFs face a set of distinct philosophies illustrated by SCHD, SPYI and SDIV. Each fund prioritizes a different route to income generation - dividend quality and growth, options-enhanced yield, or a global hunt for the highest dividend payers - and the performance and risk profiles reflect those choices.
The three approaches
- SDIV - Global yield maximizer: targets high-paying equities across a broad set of countries.
- SPYI - Options-engineered income: combines S&P 500 exposure with an options overlay to generate cash distributions.
- SCHD - Quality dividend grower: focuses on U.S. blue-chip dividend payers screened for quality, aiming to combine income with total return.
Head-to-head metrics
The funds display contrasting characteristics on price, yield, costs, and risk-return metrics:
| Metric | SDIV | SPYI | SCHD |
|---|---|---|---|
| Price | $24.96 | $53.41 | $33.45 |
| Dividend Yield | 9.03% | 12.01% | 3.14% |
| Expense Ratio | 0.58% | 0.68% | 0.06% |
| AUM | $1.21B | $11.05B | $104.16B |
| 1Y Return | +8.95% | +6.29% | +26.78% |
| YTD Return | +3.35% | +1.25% | +21.62% |
| Sharpe Ratio | 1.17 | 1.32 | 1.82 |
| Sortino Ratio | 2.34 | 2.68 | 5.28 |
| Beta | 0.38 | 0.71 | 0.22 |
| Worst 3-Month | -46.59% | -5.94% | -21.55% |
| # Holdings | 115 | 512 | 103 |
Why SCHD stands out
SCHD combines a very low expense ratio of 0.06% with a quality-screened roster of U.S. blue-chip names. The fund registers an alpha of +20.94 and a Sortino ratio of 5.28, roughly double its peers, suggesting stronger downside protection relative to volatility. Its largest sector exposures are defensive-tilted: Healthcare at 20.9% and Consumer Defensive at 20.2%. Representative holdings include Abbott Laboratories (ABT), Amgen (AMGN), Coca-Cola (KO) and Procter & Gamble (PG). The tradeoff is a lower nominal yield of 3.14% and a worst three-month drawdown of -21.55% during severe market weakness, but SCHD’s combination of income plus substantial price appreciation produced the highest total returns over the trailing 12 months (+26.78%).
SPYI’s options-overlay tradeoff
SPYI generates a 12.01% yield by layering an options program on S&P 500 exposure. Its near-99% correlation (98.99%) with the S&P 500 means investors retain indexlike risk and return characteristics while capping upside in exchange for recurring premiums. That structure has delivered smaller peak-to-trough downside in the short term - a worst three-month of only -5.94% - and the fund carries a four-star Morningstar rating and $11.05 billion in assets under management, indicating broad investor adoption. The concession is reduced capital appreciation potential in strong bull markets relative to owning the S&P 500 outright.
SDIV’s global, value-oriented search for yield
SDIV assembles income by targeting high dividend payers across more than 40 countries. Regional weights tilt toward North America (40.9%), Latin America (20.3%) and Europe (16%). Its valuation signals - a trailing P/E of 8.3x and a P/B of 1.15x - point toward a deep value posture. Yet the fund’s worst three-month loss of -46.59% illustrates the danger of pursuing yield without stringent quality filters. SDIV’s three-year earnings growth sits at -6.05%, a metric that reinforces the possibility of a dividend trap when payouts are not backed by expanding earnings.
Which fund suits which investor
| Investor Goal | Best Fit |
|---|---|
| Maximum current income, risk-tolerant | SPYI |
| Total return + steady income | SCHD |
| Global diversification + high headline yield | SDIV |
| Cost-conscious, long-term compounder | SCHD (0.06%) |
| Income with S&P 500 stability | SPYI |
Bottom line
The most counterintuitive finding is that SCHD’s lower headline yield of 3.14% has produced greater total income plus price appreciation over the trailing 12 months than SDIV’s substantially higher nominal yield. Headline yield without growth can be a treadmill; SCHD’s combination of disciplined quality screening, low cost and exposure to defensive sectors has translated into stronger total returns and superior risk-adjusted metrics within this comparison.